Skip to main content

Table 1 Patient demographics

From: Fluid management in patients undergoing cardiac surgery: effects of an acetate- versus lactate-buffered balanced infusion solution on hemodynamic stability (HEMACETAT)

CharacteristicsTotal (n = 148)Ringer’s acetate (n = 75)Ringer’s lactate (n = 73)p value*
Sex, n (%)
 Male112 (75.7)56 (74.7)56 (76.7)0.772
 Female36 (24.3)19 (25.3)17 (23.3) 
Age [years], med (IQR)67.5 (58.0–72.5)66.0 (58.0–72.0)68.0 (59.0–73.0)0.631
ASA PS [class], n (%)   1.000
 33 (2.0)2 (2.7)1 (1.4) 
 4145 (98.0)73 (97.3)72 (98.6) 
Euroscore, med (IQR)18 (17–19)18 (17–19)18 (16–19)0.542
SAPS, med (IQR)54 (44–62)54 (46–62)54 (42–62)0.945
NYHA [grade], n (%)   0.167
 011 (7.5)5 (6.8)6 (8.2) 
 134 (23.1)18 (24.3)16 (21.9) 
 269 (46.9)34 (46.0)35 (48.0) 
 328 (19.1)17 (23.0)11 (15.1) 
 45 (3.4)0 (0.0)5 (6.9) 
Preoperative ejection fraction [%], med (IQR)60 (55–65)60 (55–65)60 (55–65)0.795
Preoperative eGFR [mL/min], med (IQR)70 (53–85)73 (51–87)67 (54–83)0.507
Type of surgery, n (%)
 Composite graft (+valve#)20 (13.5)4 (5.3)16 (21.9)0.004
 Other128 (86.5)71 (94.7)57 (78.1) 
  Single valve107 (72.3)59 (78.7)48 (65.8) 
  Single valve + CABG12 (8.1)5 (6.7)7 (9.6 
  Double valve6 (4.1)4 (5.3)2 (2.7) 
  Double valve + CABG1 (0.7)1 (1.3)0 (0.0 
  Triple valve2 (1.4)2 (2.7)0 (0.0) 
Duration anesthesia [min], med (IQR)310 (266–362)305 (266–353)310 (264–364)0.937
Duration surgery [min], med (IQR)202 (170–251)205 (176–251)192 (170–264)0.812
Aortic cross clamp time [min], med (IQR)70 (56–90)67 (53–86)73 (58–97)0.172
Hypothermic circulatory arrest n (%)17 (11.56)3 (4.00)14 (19.18)0.004
Red blood cell transfusions [mL]°, med (IQR)340 (220–550)333 (223–575)350 (174–550)0.788
Time until initial hemodynamic stabilization [h], med (IQR)12.06 (9.7–13.9)12.08 (10.0–13.4)12.05 (9.1–14.1)0.649
  1. *Wilcoxon rank sum test for continuous variables and chi-square test
  2. °Fisher’s exact test for categorical variables between the Ringer’s acetate and the Ringer’s lactate study groups including autologous retransfusion and red cell concentrates
  3. #One patient in the Ringer’s lactate group